Breast Cancer

Analysis confirms benefits of combining trastuzumab and chemotherapy

Published in Cancer Weekly, July 17th, 2007

A recent meta-analysis of five major breast cancer trials has confirmed that combination treatment with the antibody trastuzumab and chemotherapy improves survival in women with operable HER-2 positive breast cancer.

At the ESMO Conference Lugano, Issa Dahabreh from the University of Athens reported the results of a meta-analysis of 5 trials involving more than 13,000 women whose breast cancer was amenable to surgery.

All the trials compared disease-free survival, overall survival and the risk of locoregional and distant recurrence of breast cancer in women given adjuvant chemotherapy alone or chemotherapy plus trastuzumab, after breast...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2007-07-17)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry